Ignite Creation Date:
2024-05-05 @ 7:43 PM
Last Modification Date:
2024-10-26 @ 9:52 AM
Study NCT ID:
NCT00723645
Status:
COMPLETED
Last Update Posted:
2015-11-30
First Post:
2008-07-25
Brief Title:
Rate and Predictors of Relapse in the Treatment of Hepatitis C Study P05181
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-life Clinical Practice in Spanish Hospitals FAST-4
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FAST-4
Brief Summary:
This is an observational multicenter nationwide study where information will be collected on the follow-up of participants with chronic hepatitis C virus HCV who have a viral response at the end of treatment with pegylated interferon alfa-2b PEG IFN alfa-2b plus ribavirin RBV administered according to the directions on the products labeling No administration of treatment is planned as a result of study enrollment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None